AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02450188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBST
Description: The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
Study NCT01223638 — intervention group
Intervention type: OTHER
Intervention: Audiometry
Description: Audiometry
Study NCT01557569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
Study NCT01557569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
Study NCT02366858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 19 gauge
Description: Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
Study NCT02366858 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge
Description: Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
Study NCT00389727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study NCT05063890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Specific Post Isometric Relaxation MET
Description: 3-5 reps of Post Isometric Relaxation MET targeted at muscles of the neck prone to get short
Study NCT05063890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Movement Specific Post Isometric Relaxation MET
Description: 3-5 reps of Post Isometric Relaxation MET targeted at specific movements of the cervical spine
Study NCT05063890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral postero-anterior glide
Description: 3 sets of unilateral posteroanterior glide (10-15 oscillations) at the involved segment
Study NCT05063890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heating and TENS
Description: Heating and TENS for 10 minutes
Study NCT01516229 — intervention group
Intervention type: DRUG
Intervention: somatropin
Description: Prescription of somatropin at the discretion of the physician
Study NCT00959712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ECA Interaction
Description: The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
Study NCT03003962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Anti-PD-L1 monoclonal Antibody monotherapy
Study NCT03003962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel + carboplatin
Description: Chemotherapy Agents
Study NCT03003962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + cisplatin
Description: Chemotherapy Agents
Study NCT03003962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + carboplatin
Description: Chemotherapy Agents
Study NCT03003962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + cisplatin
Description: Chemotherapy Agent
Study NCT03003962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + carboplatin
Description: Chemotherapy Agent
Study NCT02322021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
Study NCT02618629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-Z-215
Description: Single oral dose of 20mg Z-215 and 14C-Z-215 solution
Study NCT02121704 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Endoscope Imaging (Scope Guide)
Study NCT03356015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L Polyethylene Glycol
Description: 4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
Study NCT03356015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3L Polyethylene Glycol
Description: 3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
Study NCT03905135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Interleukin-15 (IL-15) will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose level of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
Study NCT03905135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Interleukin-15 (IL-15) will be administered by continuous intravenous infusion at the maximum tolerated dose (MTD) or maximum administered dose (MAD) on days 1-5 of each of six cycles
Study NCT03905135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab (intravenous (IV) over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
Study NCT02783183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHD1119
Description: 2 by 2
Study NCT02783183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119
Description: 2 by 2
Study NCT02783183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: 2 by 2
Study NCT02783183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica
Description: 2 by 2
Study NCT01639443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Predictive no-show overbooking
Description: During intervention period, every Veteran scheduled for an endoscopy will be offered fast-track offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot.
Study NCT03563781 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sentinel node detection
Description: Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
Study NCT00490555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 10 g
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
Study NCT02322021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will receive 2 tablets, which when combined will make up the required doses of E2609 or placebo, to be administered orally once per day (QD) with food.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
Study NCT01702571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
Study NCT03438318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.
Study NCT03438318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-Mercaptopurine
Description: Maintenance:60mg/m2 daily for 24 months.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Maintenance:60mg/m2 daily for 24 months.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
Study NCT04649749 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI scan
Study NCT00993473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE901)
Description: 100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~* Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~* Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~* Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~* HbA1c \<7.5%.
Study NCT00993473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH) insulin
Description: NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine
Study NCT03438318 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
Study NCT00993473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
Study NCT00993473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
Study NCT01202357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Case Management
Description: Community case management for psychosis by designated key-worker according to specified protocol
Study NCT01202357 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Community Case Management
Description: Community case management for psychosis by designated key-worker according to specified protocol
Study NCT03020316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Mentor
Description: A volunteer with a similar disease as the subject
Study NCT03020316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcendental Meditation
Description: A meditation technique
Study NCT05056818 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records and past imaging examinations
Study NCT01927848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosehip
Description: Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
Study NCT01927848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
Study NCT01751425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00406094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: 10mg
Study NCT00406094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01295229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic Roux-en-Y gastric bypass (RYGB) procedure
Description: The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
Study NCT01295229 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
Study NCT04180774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tag-7 gene modified inactivated tumor cells
Description: Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
Study NCT02578771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZuraPrep with 70% IPA
Description: Apply topically
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-asparaginase
Description: Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
Study NCT01358253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
Study NCT01105182 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation
Description: Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
Study NCT00108550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
Study NCT00108550 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Inert placebo
Description: Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
Study NCT00460850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40KD) [PEGASYS]
Description: 180 micrograms sc weekly for 48 weeks
Study NCT02578771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep with 70% IPA
Description: Apply topically
Study NCT02578771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZuraPrep without 70% IPA
Description: Apply topically. 0% IPA
Study NCT02578771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep without 70% IPA
Description: Apply topically. 0% IPA
Study NCT02578771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep CHG/IPA Teal Tint
Description: Apply topically
Study NCT02578771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChloraPrep CHG/IPA Teal Tint
Description: Apply topically
Study NCT00490555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: dutasteride 0.5 mg orally
Study NCT02578771 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Apply topically
Study NCT01751425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT01751425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO
Study NCT01751425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT00490555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone (DMPA)
Description: 300 mg DMPA injection on Day 0 IM (into the muscle)
Study NCT00490555 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testosterone gel
Description: Place gel applied daily for 12 weeks
Study NCT02578771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Apply topically
Study NCT04359329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
Study NCT01241773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: One 400 mg tablet twice daily for 7 days
Study NCT01241773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + raltegravir
Description: Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
Study NCT01241773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Two 75 mg capsules once daily for 7 days
Study NCT01241773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + efavirenz
Description: Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
Study NCT02315950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Botulinum toxin and cineMRI-UDS
Description: The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.